For years liberals have called RFK Jr a QUACK… an ALARMIST… and a CONSPIRACY THEORIST.
But now it appears HE WAS RIGHT about a COVID lab leak…
He was RIGHT about microplastics…
And he was RIGHT about FDA corruption.
Now, he’s issued a terrifying new warning that Americans need to hear in 2025.
Millions are in the crosshairs…
And if you were born before Jan 1st, 1965, THIS affects you most of all.
Get the full facts here.
P.S. Liberals will call THIS crazy too, until they see the data. Learn why RFK Jr is warning Americans about this emerging health crisis before it’s too late. Watch this video now.
A MESSAGE FROM OUR PARTNER
What’s Changing Inside U.S. Pharma Right Now
The Food and Drug Administration (FDA) recently awarded six new “National Priority” review vouchers, bringing the total to 15 in this pilot program. In selected cases, drug reviews may now be completed in one to two months, compared to the standard 10-12 months.
These vouchers go to companies who commit to U.S. manufacturing, affordability, or targeting urgent health needs.
|
Why This Matters for the Market
Regulatory speed isn’t just a procedural change — it affects how quickly companies can reach the market, secure partnerships, or attract financing. When review timelines shrink, the competitive landscape shifts, and certain firms gain a meaningful head start.
What Deserves Attention Now
Watch for companies that:
• Received one of these new vouchers
• Have late-stage drugs approaching FDA review
• Can scale production domestically faster than peers
These are often the first names to benefit when approval pathways accelerate.
Partner Resources:
▶ ALERT: MAJOR BANKS AT RISK! Government could seize your savings
—Learn how to safeguard your wealth with GOLD.
(by Sanctuary Metals)
▶ No Interest Until 2027? Yes, Really.
(by FinanceBuzz)
▶ 0% APR Cards Just Dropped — Apply Before They’re Gone
(by FinanceBuzz)
Final Note
When timelines compress, momentum tends to form earlier than investors expect. Companies positioned for rapid review or expansion often move ahead of the broader narrative — long before headlines catch up.
Deniss Slinkins,
Global Financial Journal
